RSS Feed
Search Ask-Cato.com
Tags
510(k) adverse events ANDA biologics biomarkers biosimilar biotech BLA cancer Cato BioVentures Cato Research CDER CDRH clinical investigator clinical research clinical trials CMC conference CROs drug development eCTD efficacy FDA funding GlobalSubmit guidance IND in vitro diagnostics labeling manufacturing marketing application medical devices NDA nonclinical research oncology Orphan Drug Designations pediatric PMA postmarketing protocol safety statistical analysis transparency venture capital webinarCategories
- Clinical Trials (70)
- Conferences and Meetings (36)
- eCTD (30)
- FDA (110)
- Guest Posts (5)
- Health Canada (7)
- Industry News (88)
- Project Management (1)
- Publications (7)
- Regulatory Strategy (57)
- Social Media (7)
- Statistics (9)
- Uncategorized (1)
- Venture Capital (11)
- Webinars (26)
Tag Archives: fina
Biotech Financing: Those That Adapt to Change Will Survive
In the October issue of Biotechnology Focus, Cato Research’s very own Chief Financial Officer and Principal of Cato BioVentures, Daniel Pharand, discusses the recent shift and latest trends in financing within the biotechnology industry. “There have been a number of … Continue reading
Posted in Publications, Venture Capital
Tagged biotech, Cato BioVentures, Cato Research, fina, venture capital
1 Comment
